Engineered t cells take on deadly childhood brain cancer
NCT ID NCT05478837
First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This early-phase trial tests a new treatment for children and young adults with a rare, aggressive brain tumor called H3.3K27M-mutated diffuse midline glioma. The treatment involves taking a patient's own immune cells (T cells), genetically modifying them in the lab to recognize the tumor, and giving them back after a short course of chemotherapy. The main goals are to see if the treatment is safe and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified T cells (KIND T cells) plus chemotherapy (cyclophosphamide and fludarabine)
- What this could lead to
- If it works, this could point toward a new treatment option for a rare and aggressive brain tumor that currently has few effective therapies.
- What could go wrong
- This is a very early, small phase 1 trial with only 12 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors or improve survival, and there are risks from the chemotherapy and the modified cells themselves.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle an incurable childhood brain tumor?
- Could an antiparasitic drug boost radiation against childhood brain tumors?
- New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
- New hope for deadly brain tumors: Drug-Radiation combo trial opens
- Experimental vaccine combo takes on childhood brain cancer
- New hope for kids with DIPG: major trial compares two treatments